02.10.15
Bio-tech company Algisys is developing omega-3 fatty acids, primarily EPA, from microalgae.
AlgiSys’ environmentally sustainable products are designed to replace or enhance EPA omega-3 oils derived from fish oil.
The company has been performing its technology development and scale-up work through technical collaborations with several partners including Michigan Biotechnology Institute (“MBI”) and several internationally renowned European research facilities. Michael LoPresti, CEO and co-founder said, “By using the company’s core expertise, these collaborators are helping to accelerate efforts necessary for commercialization of the company’s technology.”
Dr. James Wynn at MBI commented, “Using a “non-GMO” fermentation-based approach to produce EPA-rich oil has enormous potential human health benefits. AlgiSys is developing a truly ground-breaking product. AlgiSys provides high levels of sterility and process control, which will produce a purer and more consistent algae product. It is MBI’s mission to help nascent technologies such as this to make the successful transition from promising laboratory finding to a world-changing commercial technology.”
AlgiSys said it uses proven fermentation and downstream processing technology to efficiently scale and accelerate the production of EPA oil at commercial levels.
For more information: www.algisys.com
AlgiSys’ environmentally sustainable products are designed to replace or enhance EPA omega-3 oils derived from fish oil.
The company has been performing its technology development and scale-up work through technical collaborations with several partners including Michigan Biotechnology Institute (“MBI”) and several internationally renowned European research facilities. Michael LoPresti, CEO and co-founder said, “By using the company’s core expertise, these collaborators are helping to accelerate efforts necessary for commercialization of the company’s technology.”
Dr. James Wynn at MBI commented, “Using a “non-GMO” fermentation-based approach to produce EPA-rich oil has enormous potential human health benefits. AlgiSys is developing a truly ground-breaking product. AlgiSys provides high levels of sterility and process control, which will produce a purer and more consistent algae product. It is MBI’s mission to help nascent technologies such as this to make the successful transition from promising laboratory finding to a world-changing commercial technology.”
AlgiSys said it uses proven fermentation and downstream processing technology to efficiently scale and accelerate the production of EPA oil at commercial levels.
For more information: www.algisys.com
